SCHEMBL16334263

SCHEMBL16334263

CCc1c(N)n(C)c(=O)[nH]c1=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.66
EPHX2 P34913 1/20 0.46
MAPT P10636 3/20 0.43
GLA P06280 1/20 0.43
POLB P06746 1/20 0.42
ATM Q13315 1/20 0.41
GFER P55789 1/20 0.40
KDM4E B2RXH2 6/20 0.38
GAA P10253 3/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM1A O60341 1/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
LMNA P02545 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CDK1 P06493 1/20 0.36
TPI1 P60174 1/20 0.36
CHRNB2 P17787 1/20 0.36
ADRA1D P25100 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9972763 0.78 SMN1; SMN2 (0.49) SMN1; SMN2MAPTKDM4EALDH1A1KDM1A
SCHEMBL16334483 0.76 SMN1; SMN2 (0.47) SMN1; SMN2MAPTGLAPOLBATM
SCHEMBL1546631 0.74 EPHX2 (0.52) SMN1; SMN2EPHX2MAPTGLAPOLB
SCHEMBL15667389 0.72 EPHX2 (0.50) SMN1; SMN2EPHX2MAPTGLAPOLB
SCHEMBL17582661 0.72 SMN1; SMN2 (0.43) SMN1; SMN2EPHX2MAPTGLAKDM4E
Hydrochloric Acid SCHEMBL30362216 0.71 EPHX2 (0.49) SMN1; SMN2EPHX2MAPTGLAPOLB
SCHEMBL6013388 0.71 MAPT (0.59) SMN1; SMN2EPHX2MAPTGLAPOLB
SCHEMBL2553972 0.68 EPHX2 (0.46) SMN1; SMN2EPHX2MAPTGLAPOLB
SCHEMBL1546077 0.68 CDK1 (0.52) SMN1; SMN2EPHX2MAPTGLAPOLB
SCHEMBL9412532 0.68 KDM4E (0.51) SMN1; SMN2EPHX2MAPTGLAATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2026-05-07 US disclosed
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2024-09-26 US disclosed
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2024-04-23 US disclosed
EP-3421462-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2023-04-05 EP disclosed
EP-3421462-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2023-04-05 EP disclosed
US-20210300899-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2021-09-30 US disclosed
US-20210300899-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2021-09-30 US disclosed
US-11014909-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2021-05-25 US disclosed
US-11014909-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2021-05-25 US disclosed
US-20200283407-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2020-09-10 US disclosed
US-20150196561-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-07-16 US disclosed
US-20150196561-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-07-16 US disclosed
US-20150175573-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-06-25 US disclosed
US-20150175573-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-06-25 US disclosed
US-20150175573-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-06-25 US disclosed
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2015-01-01 US disclosed
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2015-01-01 US disclosed
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2015-01-01 US disclosed
WO-2014207601-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2014-12-31 WO disclosed
WO-2014207601-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2014-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS HTR6, HTR3C, OPRD1 SMN1; SMN2 614/4885EPHX2 4258/4885MAPT 556/4885
US-20150196561-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS SNCA, DRD1, DRD2 SMN1; SMN2 2561/4885EPHX2 1795/4885MAPT 81/4885
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, HTR1D SMN1; SMN2 1161/4885EPHX2 4660/4885MAPT 300/4885
US-20210300899-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D SMN1; SMN2 1161/4885EPHX2 4660/4885MAPT 300/4885
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D SMN1; SMN2 1161/4885EPHX2 4660/4885MAPT 300/4885
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS SNCA, DRD1, DRD2 SMN1; SMN2 2561/4885EPHX2 1795/4885MAPT 81/4885
US-20150175573-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D SMN1; SMN2 1161/4885EPHX2 4660/4885MAPT 300/4885
US-20200283407-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, SNCA SMN1; SMN2 3330/4885EPHX2 1684/4885MAPT 134/4885
US-11014909-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, SNCA SMN1; SMN2 3330/4885EPHX2 1684/4885MAPT 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.